News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Itonis Pharmaceuticals Update On Company Direction With Emesyl And Licensing Of App For Medical Marijuana Point of Purchase


3/27/2014 11:08:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAGUNA HILLS, CA--(Marketwired - March 26, 2014) -

Itonis, Inc. (PINKSHEETS: ITNS) today issued the following update to its shareholders:

The Company recently announced that it had entered into a letter of intent to license a proprietary mobile app from MyECheck, Inc. to facilitate point of purchase transactions for medical marijuana, gambling and general retail sales. We are on track to finalize the licensing details soon. Through our pharmaceutical relationships, we noticed an unmet demand regarding medical marijuana and the point of sales from medical suppliers. We believe that there is a significant revenue opportunity in addressing this demand with MyECheck's proprietary payment app and connecting it to the medical marijuana sector.

We also announced that Dr. Charles Hensley approved the Emesyl™ nausea remedy for manufacturing. Dr. Hensley tested the different samples sent by the manufacturer and has selected the more superior sample to be used for production.

We are proud and excited about the future in both of these ventures and we will continue to work hard delivering quality and profitable products to our customers and shareholders.

We plan to update our shareholders soon on the finalized licensing with MyECheck, Inc. and the next steps on manufacturing Emesyl™.

Thank you for your continuing support of the Company.

Mark Cheung
CEO / President

About Itonis, Inc.

Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


Contact:
Itonis, Inc.
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES